CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend is a research peptide combination pairing the GHRH analog CJC-1295 (No DAC) with the selective growth-hormone secretagogue Ipamorelin. Laboratory investigators use this pairing to examine coordinated stimulation of the growth-hormone axis through two distinct receptor systems. The blend is supplied exclusively for in-vitro and controlled laboratory research applications. It is not intended for any form of consumption or administration outside experimental model systems.

CJC-1295 (No DAC) binds GHRH receptors on somatotroph cells, activating adenylate cyclase and elevating intracellular cAMP to promote growth-hormone gene transcription and release. Ipamorelin selectively engages the ghrelin receptor GHS-R1a, triggering calcium-dependent signaling that further amplifies GH secretion. When studied together, the dual-receptor input produces a coordinated pulse that more closely models endogenous GH release patterns than either ligand alone. This complementary mechanism is the primary rationale for their combined use in mechanistic research.

Investigators employ the blend to probe synergistic growth-hormone release dynamics in pituitary cell cultures and isolated tissue preparations. Studies focus on receptor crosstalk between GHRH-R and GHS-R1a pathways, pulse amplitude modulation, and feedback interactions involving somatostatin. The combination also serves as a tool for examining second-messenger integration and the temporal characteristics of physiological GH secretory episodes under controlled laboratory conditions.

Experimental models consistently demonstrate that concurrent GHRH-receptor and ghrelin-receptor activation yields greater GH output than either stimulus applied separately. This synergy is attributed to complementary intracellular signaling cascades that converge on the secretory machinery of somatotrophs. Research using the blend has helped clarify how dual-pathway stimulation can generate more robust, physiologically patterned GH pulses. Such findings inform broader understanding of hypothalamic-pituitary regulation without implying any applied use outside the laboratory.

The blend is intended solely for in-vitro assays and laboratory model systems. Researchers typically reconstitute lyophilized material in appropriate sterile solvents under aseptic conditions and store aliquots according to standard peptide-stability protocols. Experimental design should account for the short half-life of CJC-1295 (No DAC) relative to DAC-containing analogs and the high receptor selectivity of Ipamorelin. All work must remain confined to controlled research environments.